SPY336.64+1.75 0.52%
DIA278.43+0.93 0.34%
IXIC11,270.49+102.98 0.92%

Viveve Says 'Achievement of primary efficacy endpoint in 3-arm SUI feasibility study demonstrates significant separation between CMRF treatment arm and inert sham arm'

Benzinga · 08/25/2020 10:05